Commonly Used Quality of Life and Symptom Measurement Scales

Publication
Article
OncologyONCOLOGY Vol 16 No 9
Volume 16
Issue 9

On the following pages are examples of commonly used scales for evaluating quality of life and symptoms associated with anemia in patients with cancer. Please note that some of the scales are copyrighted (and marked as such herein) and may not be reproduced in anyway without the express written consent of the copyright holders.

On the following pages are examples of commonly used scales for evaluating quality of life and symptoms associated with anemia in patients with cancer. Please note that some of the scales are copyrighted (and marked as such herein) and may not be reproduced in anyway without the express written consent of the copyright holders.

Fatigue Symptoms Inventoty (FSI)
(Paul Jacobsen)

Multidimentional Fatigue Inventory (MFI-20)
(Ellen Smets and colleagues)

Brief Fatigue Inventory
(Charles Cleeland and colleagues)

Piper Fatigue Scale (PFS)
(Barbara Piper and colleagues)

FACIT-Fatigue Scale (Version 4)
(David Cella)

FACT-Anemia (FACT-An)
(David Cella)

EORTC: QLC-C30 (Version 3)
(Karen West)

Rotterdam Symprom Checklist
(Johanna de Haes and colleagues)

SWOG Quality of Life Questionaire
(Carol Moinpour and colleagues)

Quality of Life Index Cancer Version-III
(Carol Ferrans and Marjorie Powers)

CAncer Rehabilitation Evaluation System (CARES)
(Anne Coscarelli and Richard Heinrich)

Functional Living Index: Cancer (FLIC)
(Harvey Schipper abd Charles Olweny)

Quality of Life Index
(Cary Presant and colleagues)

L.A.S.A Scale and Quality of Lide Index Form: Form Q1
(Dianne Lindsay)

M.D. Ansderson Symptom Inventory (MDASI)
(Charles Cleeland)

McMaster Health Index Questionnaire
(Larry Chambers)

RAND 36-Item Health Survey 1.0 Questionnaire
(Judy Lewis)

 

Articles in this issue
The Molecular Basis of Cancer, 2nd Edition
Management of Anemia in Patients With Cancer
Commonly Used Quality of Life and Symptom Measurement Scales
Iron and the Anemia of Chronic Disease
Diagnosis and Management of Aplastic Anemia and Myelodysplastic Syndrome
Systematic Review of Controlled Trials on Erythropoietin to Support Evidence-Based Guidelines
What Evidence Supports Use of Erythropoietin as a Novel Neurotherapeutic?
Psychological Outcomes Associated With Anemia-Related Fatigue in Cancer Patients
Recombinant Human Erythropoietin in Cancer-Related Anemia
When Is it Justified to Treat Symptoms? Measuring Symptom Burden
Overcoming Barriers to Erythropoietic Therapy
Patient Communication and Strategies for Managing Fatigue
The Potential for Anemia Treatment to Improve Survival in Cancer Patients
Blood Substitutes: How Close to a Solution?
Anemia in Cancer Patients: Significance, Epidemiology, and Current Therapy

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content
Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.